Psilocybin breakthrough therapy for major depression

The US FDA designated psilocybin, a compound found in hallucinogenic mushrooms, as a breakthrough therapy for the treatment of the Major Depressive Disorder (MDD) for the second year.

Psilocybin potentially offers a short-acting compound that imparts profound alterations in consciousness and could enable long-term remission of depressive symptoms.

Depression is the world’s leading cause of disability, affecting more than 300 million people worldwide. 

Usona Institute is planning to begin phase 2 clinical trials testing the efficacy of psilocybin for major depressive disorder

A study found that psilocybin is very effective at reducing symptoms in people with treatment-resistant depression. It also shows that psilocybin can help people become more optimistic and it is an effective way to treat addiction to tobacco and alcohol.